Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum
- 31 August 2017
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 69 (12) , 2359-2369
Abstract
Objective: Patients with definite systemic sclerosis (SSc) who lack fibrotic features can be stratified into an intermediate stage of disease severity between preclinical/early SSc (EaSSc) and fibrotic subsets (limited cutaneous SSc [lcSSc] and diffuse cutaneous SSc [dcSSc]). The aim of the present study was to molecularly characterize nonfibrotic SSc and EaSSc on the basis of a broad panel of serum markers of inflammation and tissue damage, in order to increase the knowledge of the pathophysiologic mechanisms underlying SSc progression before the development of fibrosis.Methods: An 88‐plex immunoassay was performed in serum samples from a discovery cohort composed of 21 patients with EaSSc (meeting the LeRoy and Medsger criteria), 15 with nonfibrotic SSc (meeting the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria, without skin or lung fibrosis), and 11 healthy controls. Analyte concentrations that were consistently significantly different at the exploratory P value threshold of 0.1 were selected for replication analysis in a larger group composed of 47 patients with EaSSc, 48 with nonfibrotic SSc, and 43 healthy controls, as well as 51 patients with lcSSc and 35 with dcSSc. The value of the replicated molecules in predicting SSc progression (at a family‐wise error rate of 0.05) was tested.Results: Based on the results of the explorative analysis, 16 molecules were selected for testing in the replication set. The results showed that CXCL10, CXCL11, tumor necrosis factor receptor type II (TNFRII), and chitinase 3–like protein 1 levels were significantly increased in patients with EaSSc and those with nonfibrotic SSc as compared to healthy controls. The disease in patients with high concentrations of CXCL10 and TNFRII was also characterized by a faster rate of progression from EaSSc and from nonfibrotic SSc to worse disease stages.Conclusion: SSc patients with preclinical/early SSc and those with established, yet nonfibrotic, disease exhibit clear molecular alterations that are associated with faster rates of disease evolution. These data open novel avenues for disease interception in SSc.Keywords
Funding Information
- European Research Council (ERC-2011-StG)
This publication has 30 references indexed in Scilit:
- The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesisAnnals of the Rheumatic Diseases, 2016
- Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patientsRheumatology, 2016
- Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc)Autoimmunity Reviews, 2015
- Role of class II human leucocyte antigens in the progression from early to definite systemic sclerosisRheumatology, 2014
- A Multiplex Immunoassay for Human Adipokine ProfilingClinical Chemistry, 2010
- Screening for pulmonary arterial hypertension in systemic sclerosisEuropean Respiratory Review, 2009
- SclerodermaNew England Journal of Medicine, 2009
- Interstitial Lung Disease in Systemic SclerosisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Mononuciear Cellular Infiltrates in Clinically Involved Skin from Patients with Systemic Sclerosis of Recent Onset Predominantly Consist of Monocytes/MacrophagesPathobiology, 1995
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980